Navigation Links
Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
Date:9/23/2011

cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver including metastatic melanoma to the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relat
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
2. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
3. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
4. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
5. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
6. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
7. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
8. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
9. Delcath on Preliminary List of Additions to Russell Microcap® Index
10. Delcath to Present at the JMP Securities Research Conference
11. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 ... Market by Application (Neuro & Spine Surgery, Plastic and Reconstructive Surgery, ... User (Hospitals, Outpatient Facilities) - Global Forecast to 2020", ... to reach $806.6 Million by 2020 from $402.2 Million ... to 2020.. Browse   7 ...
(Date:4/1/2015)... 31, 2015 Research and Markets ... the "Metabolic Testing Market by Product (CPET, ... (Critical Care, Lifestyle Diseases), by Technology (REE, Body ... - Global Forecast to 2019 " report ... testing market is expected to reach $475.75 million ...
(Date:4/1/2015)... INDIANAPOLIS , April 1, 2015 Eli Lilly ... results for the first quarter of 2015 on Thursday, April ... that day with the investment community and media to further ... will begin at 9:00 a.m. EDT. Investors, media, and the ... call through a link that will be posted on Lilly,s ...
Breaking Medicine Technology:Surgical Microscopes Market Worth $806.6 Million by 2020 2Surgical Microscopes Market Worth $806.6 Million by 2020 3Surgical Microscopes Market Worth $806.6 Million by 2020 4Global Metabolic Testing (CPET, Body Composition Analysis, ECG, Portable System) Market 2015-2019 - REE, Body Composition Analysis for Gyms, Sports & Hospital 2Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement 2
... March 6, 2012   Sunpeaks Ventures, Inc. ... Ventures") is pleased to provide this corporate update ... Ventures, through the recent acquisition of its wholly ... the specialty drug distribution sector.  The U.S. pharmaceutical ...
... 6, 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ... of novel therapeutics targeting cancer metabolism, announced today that ... to the U.S. Food and Drug Administration (FDA) to ... Company,s lead mitochondrial inhibitor. "I am ...
Cached Medicine Technology:Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 2Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 3Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 2Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 3
(Date:4/1/2015)... York (PRWEB) April 01, 2015 The ... of Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ) has scheduled ... calendar for the Philadelphia Court of Common Pleas, the ... 206, City Hall. Court records indicate that the proceeding ... on behalf of Risperdal users who experienced gynecomastia (male ...
(Date:4/1/2015)... It all began at home in the kitchen of Shoosha ... mission to create a line of skincare for moms and ... Now, Shoosha Truly Organic is the only complete line of ... contain a minimum 95% certified organic ingredients, for babies and ... be 40% thinner than adults and of course much more ...
(Date:4/1/2015)... Altamonte Springs, FL (PRWEB) April 01, 2015 ... the nation’s leading innovative specialty pharmacies, has released a ... the latest treatment guidelines for treating chronic hepatitis C ... up-to-date treatment guidelines based on information from the American ... other credible, scientific sources. , Numerous new direct-acting oral ...
(Date:4/1/2015)... Northfield, IL, Bethesda, MD, Alexandria, VA (PRWEB) April ... for Clinical Pathology (ASCP), the College of American ... and the American Society of Clinical Oncology (ASCO) ... guideline on the use of molecular marker testing ... This evidence-based guideline will help establish standard molecular ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3
... 11 HLTH Corporation,(Nasdaq: HLTH ) today announced ... cash, of its 48% minority interest in Emdeon Business ... General Atlantic,previously acquired a 52% majority interest in Emdeon ... Wygod, Chairman and Acting CEO of HLTH, said: "HLTH ...
... Washington, DC When the public considers competing arguments about ... to agree with the expert whose values are closest to ... same will hold true for nanotechnology, a key study has ... issued today by the Project on Emerging Nanotechnologies (PEN). The ...
... Md., Feb. 11 "Psoriasis Cure,Now," a nonprofit ... Institutes of Health (NIH) for delivering a record ... 2007. Psoriasis research has,traditionally been underfunded at NIH. ... 159% (before inflation), but psoriasis and psoriatic,arthritis research ...
... recent years, increasing attention,has been paid to the ... In some instances, proponents of LBA made,overly-optimistic claims ... predictor in,the underwriting process. Milliman expert Jonathan Shreve, ... effective use of Lifestyle-Based,Analytics as an advance in ...
... (Amex: PTN ) announced today financial results for ... net loss of $3.8 million, or,($0.04) per basic and ... to a net loss of $6.5 million, or ($0.09) ... 2006. Total revenues for the quarter,ended December 31, 2007 ...
... to Ten Properties in New Jersey and Eighteen ... Brandywine Senior Living, a,premier owner and operator of ... the acquisition of a four-property portfolio from,Meridian Health ... New,Jersey, the portfolio has more than 380 suites. ...
Cached Medicine News:Health News:HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million 2Health News:HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million 3Health News:Nanotechnology's future depends on who the public trusts 2Health News:Psoriasis Cure Now Applauds Record Government Psoriasis Research Funding 2Health News:Milliman Expert Addresses Practical Applications of Lifestyle-Based Analytics in Risk Selection 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 6Health News:Brandywine Senior Living Completes Acquisition of Four Assisted Living Communities in New Jersey 2
... The PK Plasma-CISE™ (wire ... are single use devices that ... with minimal thermal spread and ... for superior hemostasis. The devices ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
... The 2200 is ideal for applications ... of heat. , ,The autoclavable handpiece with ... thermal cautery electrodes, allowing the physician to ... variety of procedures., ,The 2200 includes the ...
Medicine Products: